Author(s): Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M,
Abstract Share this page
Abstract The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55\% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.
This article was published in J Med Chem
and referenced in Journal of Diabetes & Metabolism